Aromasin (exemestane) [summary of product characteristics]. HPRA.

Regulatory approval published by the Health Products Regulatory Authority.

Citation

Pfizer Healthcare Ireland. Aromasin 25 mg coated tablets (Exemestane) [summary of product characteristics]. Health Products Regulatory Authority website. https://assets.hpra.ie/products/Human/23117/Licence_PA0822-111-001_09012025155108.pdf. Revised January 2025. Accessed May 25, 2025.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer (EBC), following 2 – 3 years of initial adjuvant tamoxifen therapy. 1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) ER positive Invasive Breast Carcinoma Exemestane